search
Back to results

The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses (Rota-biome)

Primary Purpose

Rotavirus Infections, Intestinal Bacteria Flora Disturbance, Reaction - Vaccine Nos

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rotavirus Infections

Eligibility Criteria

18 Years - 35 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 28 days prior to starting antibiotics (day -98). A subject with a clinical abnormality or laboratory parameter outside the reference range may be included if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
  • Male between 18 and 35 years of age, inclusive at the time of signing the informed consent
  • Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form
  • Normal defecation pattern (defined as ≤3x/ day and ≥3x/week)

Exclusion Criteria:

  • Subject has had a major illness in the past 3 months or any significant chronic medical illness that the investigator would deem unfavorable for enrollment, including inflammatory diseases.
  • Subject with any history of immunodeficiency
  • Subjects with a history of any type of malignancy
  • Subject with a history of thrombocytopenia or bleeding disorder
  • Subject has a past or current gastrointestinal disease which may influence the gut microbiota
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • History of alcoholism and/or drinking more than an average of 5 units of alcohol per day
  • The subject has received an investigational product within three months of day 0 of the current study

Sites / Locations

  • Academic Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Control

Broad-spectrum antibiotics

Narrow-spectrum antibiotics

Arm Description

Control group - subjects will receive no antibiotics followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine

Subjects will receive 7 days of pre-treatment (days -9 to -3) with: Ciprofloxacin 500mg 2dd1 Vancomycin 250mg 3dd2 Metronidazole 500mg 3dd1 followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine

Subjects will receive 7 days of pre-treatment (days -9 to -3) with: • Vancomycine 250mg 3dd2 followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine

Outcomes

Primary Outcome Measures

Height of serum anti-rotavirus Immunoglobulin A (IgA) response
Geometric Mean Concentration (GMC)

Secondary Outcome Measures

Time to positivity for serum anti-rotavirus Immunoglobulin A (IgA) and G (IgG) response
(days)
Change in pre and post-vaccination anti-rotavirus (anti-RV) serum neutralizing antibodies measured by Geometric Mean Concentration (GMC)
Change in pre and post-vaccination anti-RV serum IgG response measured by Geometric Mean Concentration (GMC)
Change in serum tetanus toxoid IgG response, measured as pre and post vaccination titer (international units/mL) ratio
Change in serum pneumococcal poly-saccharide-specific IgG for all vaccine strains , measure in pre and post vaccination titer (micrograms/mL) ratio
Composition of the fecal micro biome before and after antibiotics and between groups measured by the HITChip and bacterial 16S rRNA sequencing

Full Information

First Posted
August 27, 2015
Last Updated
July 24, 2017
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Centers for Disease Control and Prevention, Wageningen University and Research
search

1. Study Identification

Unique Protocol Identification Number
NCT02538211
Brief Title
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
Acronym
Rota-biome
Official Title
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
September 2015 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
February 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Centers for Disease Control and Prevention, Wageningen University and Research

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate if the intestinal microbiota influences rotavirus vaccine immune responses in healthy adult volunteers.
Detailed Description
This study will alter the intestinal microbiota in healthy adults using antibiotics and subsequently measure immune reactions to the rotavirus vaccine (Rotarix), the tetanus vaccine and the pneumococcal vaccine (Pneumo23).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rotavirus Infections, Intestinal Bacteria Flora Disturbance, Reaction - Vaccine Nos, Tetanus, Streptococcal Pneumonia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
63 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Control group - subjects will receive no antibiotics followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Arm Title
Broad-spectrum antibiotics
Arm Type
Active Comparator
Arm Description
Subjects will receive 7 days of pre-treatment (days -9 to -3) with: Ciprofloxacin 500mg 2dd1 Vancomycin 250mg 3dd2 Metronidazole 500mg 3dd1 followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Arm Title
Narrow-spectrum antibiotics
Arm Type
Active Comparator
Arm Description
Subjects will receive 7 days of pre-treatment (days -9 to -3) with: • Vancomycine 250mg 3dd2 followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Intervention Type
Biological
Intervention Name(s)
Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Other Intervention Name(s)
RotarixTM, Pneumo 23
Intervention Description
All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
Primary Outcome Measure Information:
Title
Height of serum anti-rotavirus Immunoglobulin A (IgA) response
Description
Geometric Mean Concentration (GMC)
Time Frame
28 days post-vaccination
Secondary Outcome Measure Information:
Title
Time to positivity for serum anti-rotavirus Immunoglobulin A (IgA) and G (IgG) response
Description
(days)
Time Frame
day 0 through day 28 post vaccination
Title
Change in pre and post-vaccination anti-rotavirus (anti-RV) serum neutralizing antibodies measured by Geometric Mean Concentration (GMC)
Time Frame
28 days post-vaccination
Title
Change in pre and post-vaccination anti-RV serum IgG response measured by Geometric Mean Concentration (GMC)
Time Frame
day 0 through day 28 post vaccination
Title
Change in serum tetanus toxoid IgG response, measured as pre and post vaccination titer (international units/mL) ratio
Time Frame
day 0 through day 28 post vaccination
Title
Change in serum pneumococcal poly-saccharide-specific IgG for all vaccine strains , measure in pre and post vaccination titer (micrograms/mL) ratio
Time Frame
day 0 through day 28 post vaccination
Title
Composition of the fecal micro biome before and after antibiotics and between groups measured by the HITChip and bacterial 16S rRNA sequencing
Time Frame
day -9 and day 0 pre vaccination

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 28 days prior to starting antibiotics (day -98). A subject with a clinical abnormality or laboratory parameter outside the reference range may be included if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures Male between 18 and 35 years of age, inclusive at the time of signing the informed consent Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form Normal defecation pattern (defined as ≤3x/ day and ≥3x/week) Exclusion Criteria: Subject has had a major illness in the past 3 months or any significant chronic medical illness that the investigator would deem unfavorable for enrollment, including inflammatory diseases. Subject with any history of immunodeficiency Subjects with a history of any type of malignancy Subject with a history of thrombocytopenia or bleeding disorder Subject has a past or current gastrointestinal disease which may influence the gut microbiota Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) History of alcoholism and/or drinking more than an average of 5 units of alcohol per day The subject has received an investigational product within three months of day 0 of the current study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Willem J. Wiersinga, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Academic Medical Center
City
Amsterdam
State/Province
Noord-Holland
ZIP/Postal Code
1105 AZ
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses

We'll reach out to this number within 24 hrs